H01BB02 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 193 | プラダー・ウィリ症候群 | 2 |
193. プラダー・ウィリ症候群
臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-002385-12-IT (EUCTR) | 04/06/2021 | OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME | OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUDY OF THE SAFETY AND EFFICACY ON ORAL AND SOCIAL SKILLS AND, FEEDING BEHAVIOR OF INTRANASAL ADMINISTRATIONS OF OXYTOCIN VS. PLACEBO (PHASE III CLINICAL TRIAL) - OTBB3 | Prader-Willi Syndrom;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Oxytocin Product Code: [H01BB02] INN or Proposed INN: OSSITOCINA Other descriptive name: Oxytocin | University Hospital Toulouse | NULL | NA | Female: yes Male: yes | 48 | Phase 3 | France;Belgium;Netherlands;Germany;Italy | |||
| 2 | EUCTR2021-000094-91-FR (EUCTR) | 01/04/2021 | EFFECT OF INTRANASAL OXYTOCIN ON DYSPHAGIA IN CHILDREN AND ADOLESCENTS WITH PRADER WILLI SYNDROME | EFFECT OF INTRANASAL OXYTOCIN ON DYSPHAGIA RELATED TO OROPHARYNGO-OESOPHAGEAL DYSMOTILITY TRANSIT IN CHILDREN AND ADOLESCENTS WITH PRADER-WILLI SYNDROME: A PHASE 3 STUDY (DYSMOT) - DYSMOT | Prader-Willi Syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: OXYTOCIN Product Code: H01BB02 | Toulouse University Hospital | NULL | NA | Female: yes Male: yes | 36 | Phase 3 | France |